EP0845036B1
(de)
|
1995-08-18 |
1999-06-02 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
|
US5888963A
(en)
*
|
1996-04-18 |
1999-03-30 |
Auckland Uniservices Limited |
Treatment of bone disorders with adrenomedullin
|
US6440421B1
(en)
*
|
1996-04-18 |
2002-08-27 |
Auchkland Uniservices Limited |
Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
|
JP2001524454A
(ja)
|
1997-09-26 |
2001-12-04 |
オークランド ユニサーヴィスィズ リミテッド |
治療方法
|
WO2000078339A1
(fr)
*
|
1999-06-23 |
2000-12-28 |
Shionogi & Co., Ltd. |
Inhibiteurs de contractions uterines
|
DE60027168T2
(de)
|
1999-06-23 |
2007-01-11 |
Shionogi & Co., Ltd. |
Adrenomedullin zur behandlung von störungen des harnlassens
|
FR2821080B1
(fr)
*
|
2001-02-20 |
2003-12-19 |
Sanofi Synthelabo |
Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
|
JPWO2003078460A1
(ja)
*
|
2002-03-19 |
2005-07-14 |
株式会社オンコレックス |
ペプチド、該ペプチドを含有する医薬組成物及び癌治療用医薬組成物
|
US20040121375A1
(en)
*
|
2002-09-30 |
2004-06-24 |
Bayer Pharmaceuticals Corporation |
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
|
CA2501282C
(en)
*
|
2002-10-04 |
2012-12-04 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Vasoregulating compounds and methods of their use
|
US7462593B2
(en)
*
|
2002-11-07 |
2008-12-09 |
Us Gov Health & Human Serv |
Compositions and methods for promoting angiogenesis
|
US6727277B1
(en)
|
2002-11-12 |
2004-04-27 |
Kansas State University Research Foundation |
Compounds affecting cholesterol absorption
|
DE10316583A1
(de)
|
2003-04-10 |
2004-10-28 |
B.R.A.H.M.S Aktiengesellschaft |
Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
|
CA2539467C
(en)
*
|
2003-09-08 |
2012-11-13 |
Frank Cuttitta |
Non-peptide agonists and antagonists of adrenomedullin and gastric releasing peptide
|
WO2005103720A1
(en)
*
|
2004-03-29 |
2005-11-03 |
Medstar Research Institute, Inc. |
Methods of diagnosing cardiovascular disease
|
US8703693B2
(en)
*
|
2004-03-31 |
2014-04-22 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
AU2005231395B2
(en)
|
2004-03-31 |
2011-06-16 |
The Fernstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
EP1844158A4
(de)
*
|
2004-12-06 |
2010-09-08 |
Univ Johns Hopkins |
Biomarker für entzündliche darmerkrankung
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
JPWO2006095711A1
(ja)
*
|
2005-03-07 |
2008-08-14 |
国立循環器病センター総長 |
アドレノメデュリンを用いて障害組織を再生または修復する方法
|
JP4505640B2
(ja)
*
|
2005-04-12 |
2010-07-21 |
国立大学法人 宮崎大学 |
心筋障害の予防又は治療剤
|
EP1878789A4
(de)
*
|
2005-04-14 |
2008-08-27 |
Japan As Represented By Genera |
Aus fett stammende vorläuferzelle und verwendung davon
|
DE102005036094A1
(de)
*
|
2005-08-01 |
2007-02-08 |
B.R.A.H.M.S Ag |
In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
|
US8906857B2
(en)
*
|
2005-12-01 |
2014-12-09 |
B.R.A.H.M.S. Gmbh |
Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
|
WO2007062676A1
(en)
|
2005-12-01 |
2007-06-07 |
B.R.A.H.M.S. Aktiengesellschaft |
Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
|
DE102006060112A1
(de)
|
2006-12-20 |
2008-06-26 |
Brahms Aktiengesellschaft |
Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
|
CN101945659A
(zh)
|
2008-02-19 |
2011-01-12 |
国立大学法人旭川医科大学 |
肾上腺髓质素产生增强剂
|
US9629895B2
(en)
*
|
2011-01-12 |
2017-04-25 |
University Of Miyazaki |
Method for prevention or treatment of intractable inflammatory bowel disease
|
ES2387240B2
(es)
*
|
2011-01-31 |
2013-04-26 |
Fundación Rioja Salud |
Péptido capaz de aumentar la velocidad de desplazamiento de una kinesina o su homóloga funcional sobre microtúbulos.
|
RU2662671C2
(ru)
*
|
2011-11-16 |
2018-07-26 |
Адреномед Аг |
АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ
|
SG10202006318TA
(en)
|
2011-11-16 |
2020-08-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
US11067586B2
(en)
|
2011-11-16 |
2021-07-20 |
Sphingotec Gmbh |
Adrenomedullin assays and methods for determining mature adrenomedullin
|
EP2780717B1
(de)
*
|
2011-11-16 |
2016-12-21 |
sphingotec GmbH |
Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
|
RS58340B1
(sr)
|
2011-11-16 |
2019-03-29 |
Adrenomed Ag |
Antitelo na adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za regulisanje ravnoteže tečnosti u pacijentu koji ima hroničnu ili akutnu bolest
|
HUE045940T2
(hu)
|
2011-11-16 |
2020-01-28 |
Adrenomed Ag |
Adrenomedullinhoz kötõdõ anti-adrenomedullin (ADM) antitest vagy anti-ADM antitest fragmens vagy anti-ADM nem-Ig váz egy páciens akut betegségének vagy akut állapotának kezelésében a keringés stabilizálására történõ alkalmazásra
|
CA2856136A1
(en)
|
2011-11-16 |
2013-05-23 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
US10598674B2
(en)
*
|
2013-03-20 |
2020-03-24 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
CN106164088B
(zh)
|
2014-03-20 |
2021-11-23 |
国立大学法人宫崎大学 |
长效肾上腺髓质素衍生物
|
AU2015323769A1
(en)
*
|
2014-09-26 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Stabilized adrenomedullin derivatives and use thereof
|
CN108026182B
(zh)
|
2015-09-18 |
2022-04-26 |
国立大学法人宫崎大学 |
长效肾上腺髓质素衍生物
|
EP3482208B1
(de)
|
2016-07-08 |
2023-04-12 |
SphingoTec GmbH |
Adrenomedullin zur beurteilung der kongestion in einer person mit akutem herzversagen
|
CN110167962B
(zh)
|
2016-12-16 |
2024-06-07 |
艾德里诺医药公司 |
用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
|
EP3339324A1
(de)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
|
EP3604538A4
(de)
*
|
2017-03-29 |
2020-12-30 |
University of Miyazaki |
Adrenomedullinderivat mit langzeitwirkung
|
EP3438668A1
(de)
|
2017-08-04 |
2019-02-06 |
B.R.A.H.M.S GmbH |
Diagnose und risikostratifizierung von pilzinfektionen
|
US20220268761A1
(en)
|
2017-10-18 |
2022-08-25 |
Adrenomed Ag |
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
|
EP3502706A1
(de)
|
2017-12-20 |
2019-06-26 |
B.R.A.H.M.S GmbH |
Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin
|
SG11202006686SA
(en)
|
2018-02-08 |
2020-08-28 |
Sphingotec Gmbh |
Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
JP2022526507A
(ja)
|
2019-03-29 |
2022-05-25 |
ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
バイオマーカーに基づく遠隔患者管理の処方
|
EP3715851A1
(de)
|
2019-03-29 |
2020-09-30 |
B.R.A.H.M.S GmbH |
Verschreibung von fernpatientenmanagement auf der basis von biomarkern
|
EP3871689A1
(de)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
|
CA3172349A1
(en)
|
2020-02-27 |
2021-09-02 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
|
US20230104578A1
(en)
|
2020-02-27 |
2023-04-06 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
CA3112051A1
(en)
|
2020-03-16 |
2021-09-16 |
Sphingotec Gmbh |
Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
|
JP7499533B2
(ja)
|
2020-04-02 |
2024-06-14 |
国立大学法人 宮崎大学 |
新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
|
EP4023218A1
(de)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
|
WO2022234111A1
(en)
|
2021-05-07 |
2022-11-10 |
Sphingotec Gmbh |
Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
|
WO2024023368A1
(en)
|
2022-07-29 |
2024-02-01 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
WO2024023369A1
(en)
|
2022-07-29 |
2024-02-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|